Thus, it would be relevant to investigate in biopsies obtained before treatment and early during response to therapy whether populations of AXL-overexpressing cells exist in NSCLC at baseline, as a source of rapid EMT development and primary TKI-resistance shortly after therapy initiation. Here, AXL is linked to non-small cell lung carcinoma.